SCHEMBL1945338

SCHEMBL1945338

c1cncc(CNc2nn3cc(-c4cccs4)nc3s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
FYN P06241 4/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 1/20 0.43
NTRK1 P04629 1/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
TP53 P04637 1/20 0.42
VNN1 O95497 1/20 0.42
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1943516 0.89 FYN (0.46) GSK3BFYNADORA2AKDM4EALDH1A1
SCHEMBL1947763 0.84 FYN (0.56) GSK3BCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL1946914 0.83 ADORA2A (0.50) ADORA2AKDM4EALDH1A1MAPTLMNA
SCHEMBL1946641 0.82 FYN (0.48) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2253531 0.82 CCNE1 (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1944472 0.82 FYN (0.64) FYNKDM4EALDH1A1MAPTLMNA
SCHEMBL1946840 0.81 FYN (0.47) FYNKDM4EALDH1A1MAPTNPC1
SCHEMBL1943954 0.80 PIM1 (0.50) CYP1A2CYP3A4CYP2C9CYP2C19FYN
SCHEMBL1947713 0.80 CYP1A2 (0.51) GSK3BCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1945365 0.79 FYN (0.50) FYNKDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R GSK3B 639/4885CYP1A2 1141/4885CYP3A4 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.